Related Experiment Videos
[Hematopoietic stem cell transplantation for malignant lymphoma]
1Fourth Department of Internal Medicine, Hiroshima Red Cross Hospital.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|March 31, 2000
Summary
Hematopoietic stem cell transplantation (HSCT) offers a potentially curative option for malignant lymphoma (ML) patients with treatment-resistant disease. This review covers HSCT indications, particularly for aggressive non-Hodgkin
Area of Science:
- Hematology
- Oncology
- Transplantation Medicine
Context:
- Malignant lymphoma (ML) encompasses various B-cell and T-cell neoplasms.
- Conventional chemotherapy may be insufficient for certain ML subtypes or relapsed disease.
- Hematopoietic stem cell transplantation (HSCT) is an intensive treatment modality.
Purpose:
- To review the clinical outcomes and indications for HSCT in patients with malignant lymphoma.
- To identify patient subgroups within aggressive non-Hodgkin's lymphoma who benefit from HSCT.
- To explore the role of purged HSCT in follicular and mantle cell lymphoma relapses.
Summary:
- HSCT is indicated for aggressive non-Hodgkin's lymphoma patients experiencing chemosensitive relapses or induction failures.
- Purged HSCT may enhance outcomes for follicular and mantle cell lymphoma patients with relapsed disease.
- High-dose therapy with HSCT is considered a potentially curative approach for ML refractory to standard chemotherapy.
Impact:
- This review provides guidance on selecting ML patients for HSCT.
- It highlights HSCT as a critical therapeutic option for refractory lymphomas.
- Understanding HSCT indications can optimize treatment strategies and improve patient survival.